Bioinformatics Market Size & Growth
The Global Bioinformatics Market reached US$ 16.3 billion in 2025 and is expected to reach US$ 42.0 billion by 2033, growing at a CAGR of 12.8% during the forecast period 2026-2033.
The market is currently going through a period of significant change that is being fueled by a number of trends, such as cloud computing and big data analytics, use of artificial intelligence (AI) and machine learning (ML), and integration of multi-omics data.
Furthermore, increasing adoption of genomics and personalized medicine, growing focus on drug discovery and development, demand for efficient data management and analysis and rising demand for nucleic acid and protein sequencing are driving up the size of the bioinformatics market. Due to continuous research and developments by investment and funding from the government, the market is seeing an increase in demand from North American regions with significant competitors like Illumina Inc., Thermo Fischer Scientific, Qiagen NV, and others actively operating in the market.
Bioinformatics Market Scope
| Metrics | Details |
| CAGR | 12.8% |
| Size Available for Years | 2024-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Product & Services Type, Application |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To Know more Insights - Request Free Sample
Bioinformatics Market Dynamics
Increasing Adoption of Genomics and Personalized Medicine to Drive the Growth of the Bioinformatics Market
The increasing adoption of genomics and personalized medicine is a major driver of the bioinformatics market. The study of genomic data is critical in understanding disease causes, finding biomarkers, and developing targeted therapeutics. Bioinformatics platforms and software aid in the interpretation of genomic data and the implementation of personalized healthcare treatments.
Furthermore, investigators may now completely study the cellular environment to improve our understanding of complicated human disease when combined with BioSkryb's BaseJumper Bioinformatics platform, which allows simple and dynamic visualization of multi-omic discoveries.
Growing Focus on Drug Discovery and Development will Drive the Demand for Bioinformatics Market
Bioinformatics is critical in accelerating the drug research and development process. It helps in identifying prospective therapeutic targets, forecasting drug efficacy, expediting translational drug development, and optimizing drug design, computational tools, and data analytic approaches are applied. Bioinformatics aids in the reduction of time and expense associated with drug discovery, as well as the creation of more efficient research and development pipelines.
MIMs' oncology software solution combines expression data from 16,000 patients across more than 200 cancer types to deliver crucial insights on pharmacological mechanisms of action and therapeutic synergies in unique patient situations. This is expected to drive the market growth over the forecast period.
Lack of Skilled Professionals will Hamper the Growth of the Market
The shortage of competent people in bioinformatics is limiting market expansion. Bioinformatics requires expertise in both biology and computational analysis, yet appropriately trained professionals are scarce. The fast-changing nature of the field, transdisciplinary requirements, and limited training programs all contribute to the shortfall.
As a result, organizations experience difficulties in implementing bioinformatics tools and solutions, and data analysis efficiency may suffer. Furthermore, the pace of innovation and progress in the field is slow. Addressing this issue would necessitate coordinated efforts to extend training programs, give scholarships, and promote connections between academia and industry.
Bioinformatics Market Segmentation Analysis
The global bioinformatics market is segmented based on product & services type, application, and region.
Owing to its Wide Application, the Genomics Segment Accounted for Approximately 34.3% of the Bioinformatics Market Share
The genomics segment is anticipated to dominate the bioinformatics market, owing to advances in sequencing technology, lower costs, and expanding applications in personalized medicine, disease genomics, agricultural genomics, population genomics, and other areas. Genomics is important in customizing medical treatments, identifying the genetic basis of diseases, analyzing population dynamics, and addressing big data difficulties. The genomics segment is likely to continue leading the bioinformatics market due to its broad effect and increasing demand for genomic data processing.
This program aims to improve the skills and capabilities of public health laboratories in African Union Member States by focusing on the effective use of pathogen genomic data for the objectives of detecting outbreaks and conducting disease surveillance. This continental workforce development program aims to increase African countries' capacity to use genomic and bioinformatics techniques for public health goals.
Also, many collaborations are boosting market growth. Ultima Genomics, Inc. and Genome Insight, Inc. agreed to work together to provide cancer patients with inexpensive whole genome sequencing options. Genome Insight will participate in the early access program for Ultima's high-throughput NGS instrument platform, the UG 100, and will produce an optimized version of its whole genome bioinformatics solution for Ultima's sequencing technology as part of the deal. Thus, owing to the above factors, the segment will continue to dominate the market over the forecast period.
Bioinformatics Regional Market Analysis
North America Bioinformatics Market
North America remains a major market for bioinformatics due to its established biotechnology and pharmaceutical ecosystem, advanced genomics infrastructure, extensive biomedical research activity, and strong adoption of computational approaches in life sciences.
The United States represents a particularly important market because of extensive genomic research programs, pharmaceutical and biotechnology activity, and growing integration of genomic information into biomedical research and precision medicine. The NIH's All of Us Research Program demonstrates the scale of genomic and health data being generated for research, with more than 747,000 participants represented in its June 2026 data release.
Major demand-generating applications include:
Genomics and genomic sequencing
Pharmaceutical and drug discovery research
Precision medicine
Cancer research
Clinical research
Academic and government research
Pharmacogenomics
Asia-Pacific Bioinformatics Market
Asia-Pacific is expected to offer substantial growth opportunities as countries expand genomics research, sequencing capabilities, biotechnology infrastructure, precision medicine initiatives, and computational biology capacity.
The region is also strengthening genomic surveillance and bioinformatics capabilities. WHO reports that the number of Western Pacific Region countries with in-country genomic sequencing capacity increased from 11 in 2021 to 15 in 2025, while regional initiatives continue to support sequencing, bioinformatics training, and secure data-sharing capabilities.
India represents an important opportunity because of its expanding biotechnology and life-sciences ecosystem, increasing genomic research capabilities, and growing interest in AI-enabled precision medicine. In July 2026, WHO's South-East Asia Regional Office and the University of Colombo announced a collaboration focused on AI-enabled precision medicine, workforce readiness, responsible implementation, and governance across the region.
Key regional opportunities include:
Expansion of genomic sequencing infrastructure
Growth of biotechnology and pharmaceutical research
Increasing precision medicine initiatives
Development of bioinformatics skills and research capacity
Expansion of pathogen genomic surveillance
Increasing adoption of AI and computational biology
Europe Bioinformatics Market
Europe represents a significant bioinformatics market supported by established life-sciences research capabilities, genomics programs, pharmaceutical and biotechnology industries, and increasing integration of genomic information into healthcare and research.
The region's bioinformatics ecosystem is increasingly influenced by precision medicine, genomic research, multi-omics analysis, drug discovery, and public-health genomics.
Key areas of development include:
Genomic and clinical data analysis
Precision medicine
Drug discovery and development
Multi-omics research
Cancer genomics
Pathogen genomic surveillance
Computational biology research
The growing need to analyze complex biological datasets is expected to sustain demand for advanced bioinformatics platforms, analytical tools, and computational infrastructure
Latin America Bioinformatics Market
Latin America presents emerging opportunities for bioinformatics as research institutions, healthcare systems, biotechnology organizations, and public-health programs expand genomic and computational capabilities.
Genomic surveillance represents one important application area. WHO and the International Pathogen Surveillance Network have supported initiatives involving pathogen genomics, bioinformatics, surveillance, and capacity building in the region. For example, an IPSN-supported project at the Federal University of Rio de Janeiro focuses on a computational framework for decentralized real-time untargeted pathogen genomic surveillance.
Growth opportunities include:
Genomic surveillance
Infectious disease research
Academic genomics research
Biotechnology development
Clinical genomic applications
Bioinformatics training and computational infrastructure
Middle East & Africa Bioinformatics Market
The Middle East & Africa region presents developing opportunities for bioinformatics as countries strengthen genomics, biotechnology, healthcare research, and infectious disease surveillance capabilities.
Public-health genomics is an important application area, particularly for pathogen surveillance and outbreak detection. WHO highlights the importance of sequencing capacity, bioinformatics, secure data-sharing platforms, and data-to-decision workflows in strengthening genomic surveillance systems.
Bioinformatics Market Companies
The major global players in the bioinformatics market include Illumina Inc., Thermo Fischer Scientific, Qiagen NV, Agilent Technologies, PerkinElmer, Celera Corporation, Dassault Systèmes, Data4Cure, Geneva Bioinformatics SA, and Lineage Cell Therapeutics, among others.
Recent Developments in the Bioinformatics Market
July 2026: Illumina expanded its Billion Cell Atlas program by adding three AI-native drug-development companies, including Formation Bio. The initiative uses large-scale genome-wide perturbation data to train virtual-cell models, validate biological targets and accelerate AI-driven drug discovery.
- May 2026: QIAGEN partnered with NVIDIA to advance AI-driven drug discovery using graph-based AI and curated bioinformatics knowledge. The collaboration integrates NVIDIA accelerated computing and BioNeMo with QIAGEN Digital Insights’ biomedical knowledge bases to improve identification of disease mechanisms, therapeutic targets and biomarkers.
- February 2026: Illumina launched TruPath Genome, a new whole-genome solution designed to improve detection of difficult-to-resolve genomic regions. The technology combines a simplified workflow with high-resolution genomic analysis, supporting more comprehensive research into rare genetic diseases.
- January 2026: Illumina launched Connected Multiomics, a cloud-based bioinformatics platform for large-scale multiomic data analysis and visualization. The platform integrates genomics, transcriptomics, proteomics and epigenomics with AI-enabled interpretation and DRAGEN secondary analysis to streamline biological discovery
Why Choose DataM?
Technological Innovations: Explores advancements in bioinformatics technologies, including cloud-based genomic data platforms, next-generation sequencing (NGS) data analysis, AI-assisted variant interpretation, multiomics analysis, high-performance computing, automated bioinformatics workflows, and AI-enabled biological data interpretation, supporting faster analysis of increasingly complex genomic and multiomic datasets.
Product Performance & Market Positioning: Evaluates bioinformatics platforms and solutions based on critical parameters such as analytical accuracy, processing speed, scalability, data integration, workflow automation, security, interoperability, visualization capabilities, and AI-assisted interpretation, highlighting how leading providers differentiate through high-throughput analysis, cloud scalability, integrated workflows, and support for genomics, oncology, rare disease, and multiomics research.
Real-World Evidence: Highlights the use of bioinformatics platforms across genomic research, clinical research, precision oncology, genetic disease research, population genomics, drug discovery, and multiomics studies. For example, Illumina reports that its BioInsight Platform is used by more than 3,500 organizations and 10,000 users, while supporting large-scale genomic programs involving hundreds of thousands of genomes.
Market Updates & Industry Changes: Tracks developments including the launch of cloud-based multiomic analysis platforms, AI-enabled bioinformatics solutions, advances in genomic data interpretation, high-performance sequencing analysis, and integration of AI with curated biomedical knowledge. Recent developments include Illumina's Connected Multiomics launch and QIAGEN's collaboration with NVIDIA to apply accelerated computing and AI to bioinformatics-supported drug discovery.
Competitive Strategies: Analyzes how leading companies expand through AI integration, cloud-based platforms, strategic collaborations, acquisitions, workflow automation, high-performance computing, and expanded genomic interpretation capabilities. QIAGEN, for example, is advancing AI-enabled bioinformatics through QIAGEN Digital Insights and its collaboration with NVIDIA, while Illumina is integrating sequencing, cloud infrastructure, analysis, and AI-assisted interpretation into connected bioinformatics workflows.
Pricing & Market Access: Explains pricing variations according to software licensing models, genomic data volume, computing requirements, storage needs, workflow complexity, deployment architecture, and required analytical capabilities. Market access includes cloud-based subscription and licensing models, enterprise bioinformatics platforms, sequencing-system software ecosystems, research-service providers, and integrated genomics solutions. Illumina, for example, states that its Connected Analytics offering uses annual licensing together with credits based on storage and analysis requirements.
Market Entry & Expansion: Identifies opportunities arising from growing genomic and multiomic datasets, increasing adoption of next-generation sequencing, expansion of precision medicine and oncology research, demand for scalable cloud-based analysis, and the integration of AI into biological data interpretation and drug discovery. Expansion strategies include AI-enabled product development, cloud infrastructure, localized data-analysis capabilities, strategic partnerships, and scalable solutions for research institutions, biopharmaceutical companies, and clinical genomics applications.
Target Audience
- Pharmaceutical & Biotechnology Companies
- Genomics & Life Sciences Research Organizations
- Bioinformatics Software & Platform Providers
- Next-Generation Sequencing (NGS) Companies
- Clinical Genomics & Diagnostic Laboratories
- Academic & Research Institutions
- Precision Medicine & Oncology Research Organizations
The global bioinformatics market report would provide approximately 53 tables, 54 figures and 195 Pages.
